



## **Oxford Genome Sciences Changes its Name to Oxford BioTherapeutics**

**Oxford, UK, 1 December 2008.** Oxford Genome Sciences announced today that it has changed its name to Oxford BioTherapeutics (OBT). The new name will take effect immediately and comes at an exciting time in the Company's development as it continues to advance its pipeline of promising novel antibody-based cancer therapeutics. The name reflects the company's complete focus on the discovery and development of targeted antibody medicines to address large and unmet patient needs in the field of oncology.

OBT combines its in-house capabilities in the discovery of novel targets for oncology with its partners Medarex's and Amgen's expertise in the development of antibody therapeutics to create an exciting pipeline of innovative first-in-class therapeutics for the treatment of cancer. Through these collaborations, OBT has access to the two leading technologies for generating fully human monoclonal antibodies. In addition, OBT has a collaboration with Biosite Inc., a wholly owned subsidiary of Inverness Medical Innovations, for the identification of novel protein-based disease markers for several cancer indications and for the development of companion diagnostic products aimed at improving the diagnosis, prognosis and treatment options for patients with cancer.

OBT's CEO, Dr Christian Rohlff, commented, "I am very excited by the progress we have made in developing our therapeutic antibody pipeline and the new name truly embodies the core strategic focus of the company on the development of successful antibody-based drugs for cancer, with integrated diagnostics. The adoption of a new name comes at a key turning point in the Company's development, as it evolves into an oncology-focussed clinical development organisation. With our collaborations with Amgen, Medarex and Biosite making significant progress, I am confident that our integrated approach to the development of antibody therapeutics and diagnostics will enable us to become an important player in the field of personalized medicines in oncology."

-Ends-

### **About Oxford BioTherapeutics**

Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines for oncology. OBT's strategy is to develop innovative antibody-based cancer drugs, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP<sup>®</sup> proteomic database. Through its alliances with the world leaders in antibody development (Medarex, Biosite and Amgen), OBT is in an unrivalled position to convert its novel targets into a successful therapeutic pipeline. OBT's pipeline will deliver innovative and cost-effective medicines to fulfil major unmet patient needs in the field of cancer. OBT, a privately held company, was formed in 2004 and is based near Oxford, UK.

For further information, please see [www.OxfordBioTherapeutics.com](http://www.OxfordBioTherapeutics.com)

**For further information, please contact:**

**Oxford BioTherapeutics**

Dr Christian Rohlf

Chief Executive Officer

Tel: +44 (0)1235 861770

[cr@oxbt.co.uk](mailto:cr@oxbt.co.uk)

**Citigate Dewe Rogerson**

David Dible, Amber Bielecka

Tel: +44 (0)207 638 9571

[david.dible@citigatedr.co.uk](mailto:david.dible@citigatedr.co.uk)